https://www.tiktok.com/t/ZTDEFcBNF/

Who has traveled abroad with their research peptides and what precautions did you take?

has anyone tried the MB injectable?

I have been seeing different protocols for MOT-C. Is it 5 days on 2 days off 8 week on 8 week off. Or every 3rd day for 2 weeks? I know that many cycles can be personal preference, but if using for a RS for fat loss with 30+ pounds to lose on GLP/CJC/Ipa which cycle would be best? Thanks for any feedback!

- M = Metformin - A = AOD-9604 - Z = Cagrilintide Metformin • Improves insulin sensitivity• Reduces hepatic glucose production• Activates AMPK (energy regulation pathway)• May blunt appetite in some individuals AOD-9604 (HGH Fragment 176-191) • Fragment of growth hormone• Studied for lipolysis (fat breakdown)• Does not significantly raise blood glucose like full GH• Primarily researched for stubborn fat reduction Cagrilintide • Long-acting amylin receptor agonist• Increases satiety signaling• Slows gastric emptying• Often discussed alongside GLP-1 agonists for dual appetite control Why People Stack Them: The theory behind MAZ: - Metformin → improves metabolic efficiency - AOD-9604 → supports fat mobilization - Cagrilintide → suppresses appetite So the stack aims to target: 1. Appetite control 2. Fat breakdown 3. Insulin sensitivity From multiple angles simultaneously. Important Considerations - Dosing varies widely in online discussions - Potential side effects: GI distress, nausea, hypoglycemia risk (depending on combination and individual factors) - Stacking appetite suppressants can increase nausea significantly First — important context: - Metformin is FDA-approved (prescription medication). - AOD-9604 is a research peptide (not FDA-approved for fat loss). - Cagrilintide is still in clinical development and not commercially approved in the U.S. - Combining these is not an FDA-approved protocol and should only be done under medical supervision. MAZ Stack Overview M = Metformin A = AOD-9604 Z = Cagrilintide Typical Dose Ranges: 1️⃣ Metformin Clinical ranges: - 500 mg once daily → titrated - Common therapeutic range: 1,000–2,000 mg/day divided doses Titrated slowly to reduce GI side effects. 2️⃣ AOD-9604 Research ranges often cited: - 250–500 mcg dailyUsually administered subcutaneously. Human data is limited compared to GLP-1s. 3️⃣ Cagrilintide In clinical obesity trials: - Weekly dosing - Doses studied ranged approximately 0.3 mg → 2.4 mg weekly (titrated)